ImaginAb, GE Healthcare sign master research deal to develop new PET diagnostic imaging agents

GE Healthcare Ltd. and ImaginAb, Inc. have executed a master research agreement around the development of new PET (Positron Emission Tomography) diagnostic imaging agents based on ImaginAb's antibody fragment technology. The agreement is launched with an initial exclusive collaboration around a novel cardiovascular target.

"We are very pleased to have established this collaboration with GE and particularly delighted that our first project extends ImaginAb's reach into the rapidly growing market for new PET tracers to image high-risk cardiovascular disease," said Dr. Christian Behrenbruch, CEO of ImaginAb. "As a development partner, GE Healthcare brings tremendous and much-valued expertise in radiochemistry process development and clinical translation."

"With the growing importance of biologics-based therapeutics in treating cancer and inflammation and our evolving understanding that cancer and cardiovascular disease are modulated by fundamental immune processes, we view this collaboration with ImaginAb as timely," said Marivi Mendizabal, Head of Research, GE Healthcare, Medical Diagnostics. "Our vision is that technologies, such as the ImaginAb antibody fragment platform, will enable us to rapidly develop new targeted molecular diagnostics – not just for our own clinical portfolio, but as a 'companion' diagnostic offering to antibody/drug conjugate pipelines for our strategic biopharma partnerships."

SOURCE ImaginAb, Inc.